Transient myeloproliferative disorder (TMD) is a leukemia type that occurs typically in newborns.
INTRODUCTION
Transient myeloid leukemia occurs typically in newborns with Down syndrome (DS) and is classified by the WHO as transient abnormal myelopoiesis (TAM). 28, 32 Clinical characteristics of TAM vary from asymptomatic presentation to serious conditions with hepatosplenomegaly, breathing problems and hemorrhage, based on megakaryocytic hyperproliferation, leukocytosis, anemia and thrombocytopenia. 1, 20, 28, 31, 34 Germline trisomy 21 and prenatal acquired somatic GATA1 mutations are considered to be pathognomic for TAM. [1] [2] [3] 29, 31 More recently, transient leukemia has also been reported in patients with germline trisomy 21 mosaicism and even with somatic trisomy 21, with or without GATA1 mutations. 2, 3 Non-DS transient myeloid leukemia without germline or somatic trisomy 21 is very rare, and these cases are challenging with Abbreviations: AMKL, acute megakaryoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CN-LOH, copy-neutral loss-of-heterozygosity; CN-loss, copy number loss; DS, Down syndrome; FISH, fluorescence in situ hybridization; JMML, juvenile myelomonocytic leukemia; PB, peripheral blood; PCR, polymerase chain reaction; SNP, single-nucleotide polymorphism; TAM, transient abnormal myelopoiesis; TMD, transient myeloproliferative disorder; WBC, white blood cells.
regard to clinical decision-making, as the alternative to a watch-andwait strategy is highly intensive treatment. TMD has mainly been described in hyperproliferative germline RAS-mutated transient juvenile myelomonocytic leukemia (JMML) or oligoclonal monoblastic TMD cases with germline THPO gene mutations. 4, 20 In addition, transient myelomonocytic leukemia harboring t(8;16) has been reported. 5 In transient non-DS acute myeloid leukemia (AML) M7 cases without any trisomy 21, only trisomy 12 and subclonal deletions of chromosome 7, 8 and 13 have been reported. We describe here a non-DS TMD patient without (subclonal) trisomy 21 in whom single-nucleotide polymorphism (SNP) analysis of leukemic blasts revealed a novel submicroscopic genetic aberration.
CASE REPORT
We screened the patient (35,5/7 weeks gestation) at the age of 12 days with myeloid blasts in peripheral blood (PB) (Fig. 1 
RBM15/MKL1
and MNX/ETV6) were not found. GATA1 mutation analysis (with detection limit of 5% in our hands) was negative.
The premature state of the child, the absence of clinical signs and the absence of genetic/molecular aberrations associated with AML/JMML encouraged us to choose the careful watch-and-wait strategy by consensus of the pediatric oncology team. The non-DS AMKL clone resolved spontaneously and at the age of 4 months, blood counts had completely recovered and no clone could be identified by SNP analysis anymore (Fig. 1) . The cytogenic clone was no longer present at days 83 and 132 (BM).
Based on the lack of recurrent aberrations by standard analysis, an extended search for genomic alterations was performed using Supplementary Fig. S1 ). FISH analysis using 5q31(EGR1) and 8q24(EXT1) probes on metaphases (cultured PB, day 17) demonstrated cryptic del(5)q and del (8) (Fig. 2c) , but 5q31.1-5q31.3 negative. Currently, 4 months later, the patient is in complete remission and MRD-negative after two cycles of standard AML induction treatment.
DISCUSSION
The differential diagnosis of myeloid hyperproliferation in infants Table S1 ). We here show that, in addition to conventional genetic testing such as karyotyping and mutational analyses, further genome-wide analysis can aid in the confirmation of monoclonality in rare individual non-DS TMD cases.
In our patient SNP array analysis at presentation revealed a somatic cryptic deletion (5) The other identified aberration was del(8)(q23.2q24), which was previously described once in TMD. 8 This deletion harbors the EXT1 gene, which encodes a glycoprotein that enhances cellular growth, adhesion, invasiveness and metastastic potential. 9 EXT1 is considered to be a tumor suppressor gene, and EXT1 downregulation by hypermethylation of the EXT1 promotor has been shown to reduce heparan sulphate synthesis, thereby deregulating hematopoiesis. 37 Interestingly, one previous study in DS patients addressed the role of EXT1 hypermethylation in the progression of TMD to DS-AMKL. 10 The fact that clonal evolution (+6,+19) at time of AML recurrence in our patient at the age of 11 months occurred in the clone harboring 8q(q23.2q24)
is suggestive of a leukemia-driving role of aforementioned genes at that hotspot. This is underscored by the fact that the AML M7 presented transiently with one clone containing both the 5q-and 8q-, whereas at reemergence the leukemia was biclonal: one clone with a de novo acquired uniparental disomy 5q (25% mosaic) and one clone with 8q-(no 5q-, +19,+6 [20% mosaicism]).
Hence, we add combined 8(q23.2q24) and 5(q31.1q31.3) deletions to the list of recurrent aberrations in which "'watch-and-wait" could be considered in neonatal AMKL cases (Supplementary Table S1 ) without trisomy 21 and mutated GATA1. It needs to be confirmed whether such cases are at substantial risk to develop leukemia at a later stage and what drives this clonal evolution. Therefore, ongoing international collaboration remains important.
